Printer Friendly

DOW CORNING CALLS UPON KESSLER TO IDENTIFY 'NEW INFORMATION' ECHOES ASPRS RECOMMENDATION OF NEW EXPERT PANEL

 DOW CORNING CALLS UPON KESSLER TO IDENTIFY 'NEW INFORMATION'
 ECHOES ASPRS RECOMMENDATION OF NEW EXPERT PANEL
 MIDLAND, Mich., Jan. 15 /PRNewswire/ -- Dow Corning today announced its support of the American Society of Plastic and Reconstructive Surgeons' (ASPRS) call for FDA Commissioner David Kessler to identify the "new information" that prompted his Jan. 6 moratorium on silicone breast implants.
 They called on the FDA to make available the list of documents. "Once we have the list, we will release to the public all of the scientific studies that are specified, just as we released all of the studies in our Pre-Market Approval Application (PMAA) to the public in July," said Dan M. Hayes, Jr., president and chief executive officer of Dow Corning Wright, the subsidiary of Dow Corning that makes silicone breast implants.
 He went on to say, "We have asked the FDA on at least three separate occasions through written correspondence and conference calls to let us know the documents that necessitated their action. We have yet to get a response." Hayes noted that those requests were in a Jan. 6 conference call with the FDA and other manufacturers, a Jan. 8 letter to the FDA, and a Jan. 10 conference call with the FDA and other manufacturers. "To date all we've heard are generalities on the information desired. We need the specific identification of the documents Commissioner Kessler has relied upon."
 "We are confident in the strength and accuracy of our science, particularly when it is interpreted by knowledgeable scientists," Hayes said. "We know more about silicones than almost anyone in the world. We have 30 years of scientific studies that seem to get lost in baseless innuendo and anecdotal claims made by the critics of breast implants. That science and the recent review of our submission to the FDA completed by Dr. Albert Kolbye confirm that our silicone breast implants are safe and effective."
 "We support the ASPRS call for a full evaluation of the science by a new blue-ribbon panel of scientific experts, perhaps under the auspices of an independent government agency. Experts in the fields of rheumatology, immunology and inflammation research have the base of knowledge to accurately interpret the data and studies relating to the auto-immune system, the issue cited by Commissioner Kessler in his Jan. 6 press conference. That would move this out of the arena of innuendo and speculation and back into the arena of valid science where it has always belonged. We welcome that move and another expert review of our studies," said Hayes.
 "We recognize that our detractors, including special interest groups and their friends in the plaintiff's bar, are opposed to real experts getting involved in this debate. After all, they cannot win when true science is the basis for the discussion," Hayes said.
 -0- 1/15/92
 /CONTACT: Barbara Carmichael, 517-496-6470, or home, 517-531-8072, or Robert Grupp, 517-496-6443, both of Dow Corning/ CO: Dow Corning ST: Michigan IN: HEA SU:


PS -- NY098 -- 0292 01/15/92 22:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1992
Words:500
Previous Article:KERKHOFF INDUSTRIES INC. REPORTS SECOND QUARTER RESULTS
Next Article:NFPA SAYS CONSUMERS UNION REPORT IS MISLEADING ABOUT PCBS IN SALMON
Topics:


Related Articles
DOW CORNING STRONGLY DISAGREES WITH FDA PANEL FINDING ON SILICONE BREAST IMPLANTS; PROTESTS INABILITY TO PRESENT ALL OF ITS DATA
DOW CORNING CALLS SID WOLFE CLAIMS '11TH HOUR SHADOWBOXING'
FDA CALLS FOR TEMPORARY MORATORIUM ON SILICONE GEL BREAST IMPLANTS
PLASTIC SURGEONS PLEDGE COOPERATION WITH IMPLANT MORATORIUM; DEMAND RELEASE OF NEW INFORMATION
DOW CORNING GLAD THAT FDA FINALLY IDENTIFIES WHAT CONSTITUTES NEW INFORMATION CONCERNING BREAST IMPLANTS
ASAPS STATEMENT ON RELEASE OF STUDIES & INTERNAL DOCUMENTS RELATED TO SILICONE-GEL BREAST IMPLANTS BY DOW CORNING
DOW CORNING RENEWS PLEDGE TO CONTINUED RESEARCH FOLLOWING FDA PANEL RECOMMENDATION
PLASTIC SURGEONS DISAPPOINTED IN FDA PANEL'S RECOMMENDATION TO RESTRICT IMPLANT ACCESS; CLAIM DECISION CONTRADICTS HEARING DISCUSSION
DOW CORNING ANNOUNCES $10 MILLION RESEARCH FUND TO CONTINUE STUDY OF SILICONE BREAST IMPLANT SAFETY
FIRST AND FINAL ADD TO DOW CORNING BREAST IMPLANTS.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters